Sherif Riad, a newly reported director of Ocular Therapeutix, Inc., filed a Form 3 initial statement of beneficial ownership with the SEC on November 10, 2026, disclosing no securities beneficially owned as of the event date of November 6, 2026.

Key Highlights

  • Reporting person: Sherif Riad, identified in the filing as a Director of Ocular Therapeutix, Inc. (NASDAQ:OCUL).
  • Event date: The date of the event requiring the statement is listed as November 6, 2026.
  • No securities held: Both Table I (non-derivative securities) and Table II (derivative securities) are blank; the filing states "No securities are beneficially owned."
  • Filing date: The form was filed on November 10, 2026, and signed by Todd Anderman as Attorney-in-Fact for Sherif Riad.
  • Individual filing: The form was filed by one reporting person, not as part of a group filing.

Sherif Riad's Initial Ownership Disclosure for Ocular Therapeutix

According to the filing, Sherif Riad submitted a Form 3 initial statement of beneficial ownership in connection with his role as a Director at Ocular Therapeutix, Inc., listed on NASDAQ under the ticker OCUL. The issuer's address on record for the reporting person is 14 Crosby Drive, 3rd Floor, Bedford, Massachusetts 01730.

The filing discloses that as of the event date of November 6, 2026, Riad held no securities beneficially owned, either directly or indirectly. Table I, covering non-derivative securities, and Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, both contain no entries. The filing explicitly states, "No securities are beneficially owned."

The form was signed on November 10, 2026, by Todd Anderman as Attorney-in-Fact for Sherif Riad, with the filing referencing an attached Exhibit 24 (Power of Attorney). The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires directors, officers, and certain shareholders to report their initial beneficial ownership of issuer securities.

What Was Disclosed

Sherif Riad filed an initial statement of beneficial ownership as a Director of Ocular Therapeutix, Inc. as of November 6, 2026, reporting no direct or indirect beneficial ownership of any securities of the company.